- Home
- MDIA vs NTHI Comparison
MDIA vs NTHI Comparison
Compare MDIA & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDIA | NTHI |
|---|---|---|
| Founded | 2019 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.7M | 106.0M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MDIA | NTHI |
|---|---|---|
| Price | $1.04 | $3.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 7.7K | ★ 140.4K |
| Earning Date | 11-18-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $133,336,000.00 | $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 39.52 | N/A |
| 52 Week Low | $0.54 | $2.50 |
| 52 Week High | $1.64 | $12.00 |
Technical Indicators
Market Signals| Indicator | MDIA | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 53.29 |
| Support Level | $0.86 | $3.03 |
| Resistance Level | $0.93 | $3.70 |
| Average True Range (ATR) | 0.08 | 0.28 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 18.59 | 61.92 |
Price Performance
Historical ComparisonAbout MDIA Mediaco Holding Inc.
MediaCo Holding Inc is a radio broadcasting media company operating in radio and digital advertising, premium programming, and events. It has two radio stations, WQHT-FM and WBLS-FM, which serve the New York City metropolitan area. The company generates revenue from radio and outdoor advertising sales, events including sponsorships and ticket sales, licensing, and syndication. The company has two business segments: the Audio segment and the Video segment.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.